Sirolimus in the treatment of kaposiform lymphangiomatosis

Abstract Background Kaposiform lymphangiomatosis (KLA), which is a new subtype of generalized lymphatic anomaly, is a rare disease with a poor prognosis. Currently, there is no standard treatment due to the poor understanding of KLA. Sirolimus, which is an inhibitor of mammalian target of rapamycin,...

Full description

Bibliographic Details
Published in:Orphanet Journal of Rare Diseases
Main Authors: Jiangyuan Zhou, Kaiying Yang, Siyuan Chen, Yi Ji
Format: Article
Language:English
Published: BMC 2021-06-01
Subjects:
Vascular anomaly
Lymphatic malformation
Kaposiform lymphangiomatosis
Sirolimus
Mammalian target of rapamycin
Online Access:https://doi.org/10.1186/s13023-021-01893-3

Internet

https://doi.org/10.1186/s13023-021-01893-3

Similar Items